A biopharmaceutical company has asked the U.S. Food and Drug Administration to approve a gene therapy invented at Nationwide Children's Hospital to treat a fatal form of muscular dystrophy. If successful, it would be the second therapy from the Columbus institution to hit the market.
Sarepta Therapeutics Inc. announced Thursday that it submitted the Biologics License Application for the Duchenne muscular dystrophy treatment, named SRP-9001 for now. The company is going through the agency's "accelerated"…
